Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | DRD4 | P21917 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7073067 | 1.00 | KDM1A (0.39) | KDM1ASLC6A2HTR2AHTR2CSLC6A4 | |
| SCHEMBL7486666 | 0.87 | HTR2A (0.38) | HTR2AHTR2CHTR2BSLC6A3DRD2 | |
| SCHEMBL8989718 | 0.85 | KDM1A (0.39) | KDM1ASLC6A2HTR2AHTR2CSLC6A4 | |
| SCHEMBL7076875 | 0.81 | LTA4H (0.48) | KDM1AHTR2ADRD2 | |
| SCHEMBL7781178 | 0.81 | KDM1A (0.45) | KDM1ASLC6A2HTR2AHTR2CSLC6A4 | |
| SCHEMBL8989732 | 0.81 | PRCP (0.44) | SLC6A4SLC6A3DRD2 | |
| SCHEMBL9010705 | 0.80 | SCN5A (0.44) | SLC6A2HTR2AHTR2CSLC6A4HTR2B | |
| SCHEMBL7073064 | 0.80 | HTR1A (0.50) | KDM1AHTR2AHTR2BDRD2 | |
| SCHEMBL8989703 | 0.79 | SLC18A3 (0.47) | DRD2 | |
| SCHEMBL7781226 | 0.79 | SIGMAR1 (0.45) | DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1104419-B1 | N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES, PRODUCTION AND USE THEREOF | BASF AG (DE) | 2002-05-29 | — | — | EP | disclosed |
| US-6300354-B1 | FOR THERAPY OF NEUROLEPTIC DISEASES | BASF AKTIENGESELLSCHAFT (DE) | 2001-10-09 | — | — | US | disclosed |